Belluscura POC now marketed through GoodRx®
24 February 2023
Belluscura plc
("Belluscura" or the "Company")
Belluscura's X-PLOR® portable oxygen concentrator now marketed through GoodRx®
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the X-PLOR portable oxygen concentrator ("POC") is now marketed in the US through GoodRx, Inc. www.goodrx.com The X-PLOR will be the first medical device in its field marketed by GoodRx, Inc.
GoodRx, Inc (Nasdaq: GDRX) is a leading digital healthcare platform that makes healthcare affordable and convenient for all Americans. The company offers consumers free access to transparent and lower prices for branded and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. Since 2011, GoodRx has helped consumers save over $45 billion and has been one of the most downloaded medical apps over the past decade.
Commenting on the new marketing portal, Robert Rauker, Chief Executive Officer, Belluscura plc, said:
"In our continued goal of broadening product distribution and making supplemental oxygen more accessible to people throughout the US, we are excited to have the X-PLOR marketed through GoodRx, a recognized leader in making healthcare more accessible and affordable in the US."
ENDS
For further information, please contact:
|
Belluscura plc |
www.belluscura.com |
|
Robert Rauker, Chief Executive Officer |
via MHP |
|
Anthony Dyer, Chief Financial Officer |
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin |
|
|
|
|
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
|
James Serjeant / Nicholas Chambers |
|
|
|
|
|
MHP Communications (Financial PR and Investor Relations) |
Tel: +44 (0)20 3128 8100 |
|
Katie Hunt / Pete Lambie / Matthew Taylor |
Email: belluscura@mhpc.com |
|
|
|
About Belluscura plc ( www.belluscura.com )
Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.
About RNS Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
COMPANIES COVERED:
Latest directors dealings
- 25 minutes ago Hunting
- 25 minutes ago Hunting
- 35 minutes ago Ricardo
- 55 minutes ago AstraZeneca
- 57 minutes ago Heavitree Brewery